Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

US11167004B2 · kind B2 · utility

Assignees

• REGENERON PHARMACEUTICALS, INC. · US
• SANOFI BIOTECHNOLOGY · FR

Inventors

• Allen Radin · New York, US
• Neil Graham · Croton-on-Hudson, US
• Bolanle Akinlade · White Plains, US
• Gianluca Pirozzi · Berkeley Heights, US
• Xing Sun · 安丰镇, CN
• Thomas Hultsch · Bound Brook, US
• Brad Shumel · Chappaqua, US
• Ashish Bansal · Survanagiri, IN

Key dates

• Filing date: Jul 16, 2019
• Grant date: Nov 9, 2021
• Expiry date: Jul 16, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/90
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.